%0 Journal Article
%T Neuromuscular Blocking Agent Use in Critical Care Transport Not Associated With Intubation.
%A Esteves AM
%A Fjeld KJ
%A Yonan AS
%A Roginski MA
%J Air Med J
%V 43
%N 4
%D 2024 Jul-Aug
%M 38897696
暂无%R 10.1016/j.amj.2024.03.003
%X <B>OBJECTIVE: </B>Variable indications exist for neuromuscular blocking agents (NMBAs) in the critical care transport setting beyond facilitation of intubation.<BR><B>METHODS: </B>This retrospective cohort study included adult patients (≥ 18 years) who underwent critical care transport from July 1, 2020, to May 2, 2023, and received NMBAs during transport that was not associated with intubation. The primary outcome was the indication for NMBA administration. Secondary outcomes included the characterization of NMBA use, mean Richmond Agitation Sedation Scale score before NMBA administration, sedation strategy used, and continuation of NMBAs within 48 hours of hospital admission.<BR><B>RESULTS: </B>One hundred twenty-six patients met the inclusion criteria. The most common indication for NMBA administration was ventilator dyssynchrony (n = 71, 56.4%). The majority of patients received rocuronium during transport (n = 113, 89.7%). The mean pre-NMBA Richmond Agitation Sedation Scale score was -3.7 ± 2.4. The most common sedation strategy was a combination of continuous infusion and bolus sedatives (76.2%). One hundred (79.4%) patients had sedation changes in response to NMBA administration. Seventy-two (57.1%) received NMBAs during the first 48 hours of their intensive care unit admission.<BR><B>CONCLUSIONS: </B>NMBAs were frequently administered for ventilator dyssynchrony and continuation of prior therapy. Optimization opportunities exist to ensure adequate deep sedation and reassessment of NMBA indication.